2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11405
    [D-Arg1,D-Trp5,7,9,Leu11]-Substance P 122481-75-8 98%
    [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is a potent inhibitor of cell growth in small cell lung cancer (SCLC). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is also a neuropeptide antagonist, capable of blocking colony formation stimulated by various neuropeptides (including vasopressin and bradykinin). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the mobilization of Ca2+ and the activation of mitogen-activated protein kinases induced by vasopressin or bradykinin. [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the growth of H-69 xenograft tumors in nude mice.
    [D-Arg1,D-Trp5,7,9,Leu11]-Substance P
  • HY-P11408
    [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) 349657-39-2
    [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14), a synthetic peptide, is a non-selective bombesin receptor agonist. [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) has preferred pEC50 values of 8.06 for the neurotrophin B bombesin receptor (BB1), 8.69 for the gastrin-releasing peptide bombesin receptor (BB2), and 6.71 for the orphan receptor (BB3). [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) can be used to study diseases related to bombesin receptors, such as cancer and neurological disorders.
    [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14)
  • HY-P11409
    Prion Protein (118-135), human 202121-03-7
    Prion Protein (118-135), human is the 118-135 fragment of human prion protein. Prion Protein (118-135), human induces Apoptosis. Prion Protein (118-135), human stimulates caspase-3 and -9 activities. Prion Protein (118-135), human is cytotoxic to retinal neurons. Prion Protein (118-135), human exerts neurotoxic effects.
    Prion Protein (118-135), human
  • HY-P11414
    Cys-flag peptide 1165821-46-4
    Cys-flag peptide (CDYKDDDDK) is a FLAG tag peptide containing cysteine. Cys-flag peptide has a targeted interaction for protein purification and detection. Cys-flag peptide can be used for the research of neurological disease, such as Alzheimer’s disease.
    Cys-flag peptide
  • HY-P11419
    Metamorphosin A 157622-03-2 98%
    Metamorphosin A is a neuropeptide that can be isolated from Anthopleura elegantissima. Metamorphosin A triggers metamorphosis in Hydractinia echinata.
    Metamorphosin A
  • HY-P11431
    Cyclo(Gly-Pro) 97011-16-0 98%
    Cyclo(Gly-Pro) is a cyclic dipeptide. Cyclo(Gly-Pro) can be derived from the Nterminus of the IGF-1. Cyclo(Gly-Pro) attenuates nociceptive behaviour and inflammatory response in mice.
    Cyclo(Gly-Pro)
  • HY-P11432
    PG-911 98%
    PG-911 is a full MC5R agonist (EC50 = 0.031 nM for hMC5R). PG-911 is also a full antagonist at the hMC3R and the hMC4R (Kb: 0.38 nM and 0.17 nM, respectively). PG-911 can be used in the research of neurological disorders.
    PG-911
  • HY-P11461
    Biotin-CRF, human, rat 105883-79-2
    Biotin-CRF, human, rat is a biotin-conjugated CRF (human, rat). CRF (human, rat) is a corticotropin-releasing hormone, paraventricular hypothalamic nucleus marker.
    Biotin-CRF, human, rat
  • HY-P11496
    CK2 Substrate peptide 154444-98-1
    CK2 Substrate peptide (Compound RRRADDSDDDDD) is a specific CK2 peptide substrate with Km of 13 μM. CK2 Substrate peptide can be used for the research of neurological disease, such as Alzheimer's Disease.
    CK2 Substrate peptide
  • HY-P11581
    MNP2 98%
    MNP2 is a NLRP3-ASC interaction inhibitor. MNP2 selectively binds to the PYD domain of ASC (Ka=149 nM) and blocks ASC-PYM binding (Ka=58 nM), thereby inhibiting the interaction between ASC and NLRP3 and suppressing the formation of the NLRP3 inflammasome. MNP2 inhibits IL-1β release and caspase-1 maturation, and reduces the efflux of potassium and chloride ions. MNP2 prevents mitochondrial damage and reactive oxygen species production, and significantly decreases NLRP3 inflammasome formation in neurodegenerative pathologies induced by β-amyloid, Tau protein and α-synuclein. MNP2 is applicable for the research of neurodegenerative diseases.
    MNP2
  • HY-P11593
    D-TLKIVWC 3105302-84-6
    D-TLKIVWC is a tau fibril disaggregator. D-TLKIVWC has low immunogenicity and anti-degradation properties. D-TLKIVWC disrupts intermolecular hydrogen bonds of tau via a stress-release mechanism. D-TLKIVWC can be used in the research of amyloid diseases such as Alzheimer's disease.
    D-TLKIVWC
  • HY-P11605
    Big endothelin-3 (Human, 1-41 amide) 133551-97-0
    Big endothelin-3 (Human, 1-41 amide) is a precursor molecule of the Endothelin-3 (ET-3) peptide composing of 41 amino acids.
    Big endothelin-3 (Human, 1-41 amide)
  • HY-P11629
    KBP-336
    KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.
    KBP-336
  • HY-P11637
    Mitochondrial-targeted peptide BP19
    Mitochondrial-targeted peptide BP19 is a fluorescent probe for the selective measurement of labile iron in the mitochondriairon. Mitochondrial-targeted peptide BP19 exhibits iron-selective sensing activity with mitochondrial accumulation, reduced fluorescence in iron-loaded cells, and fluorescence reinstatement upon iron chelation. Mitochondrial-targeted peptide BP19 evaluates mitochondrial labile iron levels in cultured fibroblasts with Friedreich's ataxia.
    Mitochondrial-targeted peptide BP19
  • HY-P11638
    Mitochondrial-targeted peptide BP29 98%
    Mitochondrial-targeted peptide BP29 is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 can be used for the research of Friedreich's ataxia.
    Mitochondrial-targeted peptide BP29
  • HY-P11642
    Sialorphin 131748-26-0 98%
    Sialorphin is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin is also a copper (II) ion-binding ligand. Sialorphin has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease.
    Sialorphin
  • HY-P11643
    LVV-hemorphin-7 75808-66-1 98%
    LVV-hemorphin-7 is an Angiotensin IV receptor ligand and IRAP inhibitor (IC50s: 17.6 nM for sheep adrenal IRAP; 5.0 nM for sheep cerebellum IRAP). LVV-hemorphin-7 inhibits the catalytic activity of IRAP. LVV-hemorphin-7 stimulates DNA synthesis. LVV-hemorphin-7 elicits a number of physiological effects, including cellular proliferation and memory enhancement.
    LVV-hemorphin-7
  • HY-P11668
    Gosicalcetide 2650595-42-7
    Gosicalcetide is a calcium sensing receptor (CaSR) agonist.
    Gosicalcetide
  • HY-P11671
    Xaranetide 3062244-70-3
    Xaranetide is a polypeptide with neuroprotective effects.
    Xaranetide
  • HY-P11675
    Rolzavosoritide 3067191-26-5 98%
    Rolzavosoritide is a C-type natriuretic peptide.
    Rolzavosoritide
Cat. No. Product Name / Synonyms Application Reactivity